Treace to Present at 43rd Annual J.P. Morgan Healthcare Conference
Treace to Present at 43rd Annual J.P. Morgan Healthcare Conference
PONTE VEDRA, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty and Adductoplasty Procedures, today announced that John T. Treace, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, beginning at approximately 9:00 am PT.
佛羅里達州龐特維德拉，2025年1月2日（全球新聞通訊社）—— Treace Medical Concepts, Inc.（「Treace」或「公司」）（NasdaqGS: TMCI）是一家醫療科技公司，通過其旗艦的Lapiplasty和Adductoplasty程序推動腳部畸形及相關中足畸形手術治療的根本變革。萬億.day宣佈，首席執行官John T. Treace將於2025年1月14日（星期二）在第43屆摩根大通醫療健康會議上發言，發言時間大約爲太平洋時間上午9:00。
A live webcast and replay of the fireside chat will be available on the Company's investors relations website at
公司投資者關係網站將提供現場網絡廣播及對話回放。
Internet Posting of Information
Treace routinely posts information that may be important to investors in the "Investor Relations" section of its website at . The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
信息的Internet Plus-related發佈
Treace定期在其網站的「投資者關係」部分發佈可能對投資者重要的信息。公司鼓勵投資者和潛在投資者定期查閱Treace網站獲取有關Treace的重要信息。
About Treace Medical Concepts
關於Treace Medical Concepts：Treace Medical Concepts， Inc.是一家醫療技術公司，旨在推進外科管理拇趾外翻及相關足弓畸形的護理標準。拇趾外翻是一種複雜的三維畸形，源於足部中部的不穩定關節，影響約6700萬美國人，其中Treace估計有110萬人需要每年手術治療。 Treace開創並取得了Lapiplasty 3D Bunion Correction System的專利--這是一種由儀器、植入物和外科方法組成的組合，旨在通過外科手術矯正拇趾畸形的三個平面，並固定不穩定的關節，解決拇趾畸形的根本原因，幫助病人恢復活力的生活方式。爲了進一步支持拇趾畸形患者的需求，Treace推出了Adductoplasty Midfoot Correction System，旨在重複性外科手術矯正足弓畸形，以及其Hammertoe PEEk Fixation System，旨在解決錘趾、雞爪趾和槌狀趾畸形。該公司通過推出SpeedPlate Rapid Compression Implants擴大了其足踝市場份額--這是一種具有廣泛適用性的創新固定平台，可應用於Lapiplasty和Adductoplasty手術，以及足部其他常見骨融合手術。有關更多信息，請訪問網站。
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty 3D Bunion Correction System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty and Adductoplasty procedures, as well as other common bone fusion
Treace醫療概念公司是一家醫療科技公司，旨在提升外科治療拇外翻及相關中足畸形的護理標準。拇外翻是一種複雜的三維畸形，源於位於腳中部的不穩定關節，影響大約6700萬美國人，其中Treace估計每年有110萬是手術候選人。Treace開發並申請了Lapiplasty 3D拇外翻矯正系統的專利，這是一種結合了儀器、植入物和外科方法的系統，旨在手術糾正拇外翻畸形的三個平面，並穩固不穩定的關節，解決拇外翻的根本原因，幫助患者恢復活躍的生活方式。爲了進一步支持拇外翻患者的需求，Treace推出了其Adductoplasty中足矯正系統，旨在實現中足畸形的可重複外科修正。該公司繼續在足部和腳踝市場擴大影響力，推出其SpeedPlate快速壓縮植入物，這是一種創新的固定平台，具有廣泛的適用性，適用於Lapiplasty和Adductoplasty手術，以及其他常見的骨融合手術。
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
欲了解更多關於Treace的信息，請在LinkedIn、X、Facebook和Instagram與我們聯繫。
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
聯繫方式：
Treace Medical Concepts
馬克·L·海爾
財務長
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Vivian Cervantes
IR@treace.net
投資者：
吉爾馬丁集團
薇薇安·塞萬提斯
IR@treace.net